Guidelines for Patients with Mast Cell Activation Syndrome (MCAS)

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jgold@ismp.org

1 post / 0 new
Daniel Kudryashov
Daniel Kudryashov's picture
Offline
Last seen: 1 week 4 days ago
Joined: 07/26/2018 - 19:27
Guidelines for Patients with Mast Cell Activation Syndrome (MCAS)

We are in the process of developing general guidelines for taking care of MCAS patients with anaphylaxis s/sx admitted to urgent care or ED from our outpatient Allergy clinic.

The key questions are what medications and doses are to be used (e.g. diphenhydramine IVP vs. infusion) and what level of monitoring is warranted.

There is a lack of good quality literature on this subject. I would greatly appreciate any insight or best practices you could share.

Thank you.

Daniel Kudryashov
Keck Medicine of USC